5 Key Takeaways

• 1

  ATP-sensitive potassium channel openers like QLS-111 target distal outflow and episcleral venous pressure to redefine glaucoma treatment.

• 2

  Episcleral venous pressure (EVP) is crucial in determining the lowest intraocular pressure (IOP) and can influence IOP management.

• 3

  Current glaucoma treatments primarily focus on altering aqueous humor production and drainage, neglecting distal outflow and EVP.

• 4

  QLS-111 has shown promising results in lowering IOP and EVP, demonstrating excellent tolerability in preclinical and clinical trials.

• 5

  Advancing knowledge of distal outflow pathways and EVP-targeting therapies like QLS-111 represents a significant step in glaucoma management.